ダウンロード数: 35

このアイテムのファイル:
ファイル 記述 サイズフォーマット 
bloodadvances.2023010598.pdf1.3 MBAdobe PDF見る/開く
タイトル: Cord blood transplantation for adult lymphoid neoplasms in Europe and Japan
著者: Watanabe, Mizuki
Kanda, Junya
Volt, Fernanda
Ruggeri, Annalisa
Suzuki, Ritsuro
Rafii-Elayoubi, Hanadi
Kimura, Fumihiko
Cappelli, Barbara
Kondo, Eisei
Scigliuolo, Graziana Maria
Takahashi, Satoshi
Kenzey, Chantal
Rivera Franco, Monica Magdalena
Okamoto, Shinichiro
Rocha, Vanderson
Chevallier, Patrice
Sanz, Jaime
Furst, Sabine
Cornelissen, Jan J.
Milpied, Noël J
Uchida, Naoyuki
Sugio, Yasuhiro
Kimura, Takafumi
Ichinohe, Tatsuo
Fukuda, Takahiro
Mohty, Mohamad
Peffault de Latour, Régis
Atsuta, Yoshiko
Gluckman, Eliane
著者名の別形: 渡邊, 瑞希
諫田, 淳也
鈴木, 律朗
木村, 文彦
近藤, 英生
高橋, 聡
岡本, 真一郎
内田, 直之
杉尾, 康浩
木村, 貴文
一戸, 辰夫
福田, 隆浩
熱田, 由子
キーワード: Lymphoid Neoplasia
Transplantation
発行日: 13-Feb-2024
出版者: American Society of Hematology
誌名: Blood Advances
巻: 8
号: 3
開始ページ: 640
終了ページ: 652
抄録: With the aim of identifying the different characteristics and prognostic factors of cord blood transplantation (CBT) in adult patients with lymphoid neoplasms in Europe and Japan, we conducted a collaborative study between European and Japanese registries. Patients aged 18-75 years receiving their first CBT (Europe: single CBT, n=192; double CBT, n=304; Japan: single CBT, n=1150) in 2000-2017 were analyzed. The number of patients with Hodgkin's lymphoma was higher in Europe (26% vs 5%) while that with mature T/NK-cell neoplasms was higher in Japan (20% vs 35%). The Japanese cohort comprised more elderly patients (>=50) (59% vs 39%) with higher refined disease risk index (rDRI) (high-very high: 49% vs 14%). High-very high rDRI (vs. low rDRI) was associated with inferior OS in common (Europe: HR 1.87 p=0.001; Japan: HR 2.34, p<0.001) with higher progression/relapse risks (Europe: HR 2.04, p=0.007; Japan: HR 2.96, p<0.001). Total body irradiation (TBI)-containing conditioning regimens contributed to superior OS both in Europe (vs TBI-RIC, non TBI-RIC: HR 1.93, p<0.001; non TBI-MAC: HR 1.90, p=0.003) and in Japan (non TBI-RIC: HR 1.71, p<0.001; non TBI-MAC: HR 1.50, p=0.007). The impact of HLA mismatches (>=2) on OS differed (Europe: HR 1.52, p=0.007; Japan: HR 1.18, p=0.107). Despite the different patient-disease-transplant characteristics, poor survival of patients receiving CBT for lymphoid neoplasms, especially in those with high rDRI was observed in both registries. The different impact of HLA mismatches on survival in the two registries calls attention to the fundamental differences among these populations. TBI should be considered in conditioning regimens.
記述: リンパ腫に対する臍帯血移植の予後予測因 --日欧国際共同研究--. 京都大学プレスリリース. 2023-12-19.
著作権等: © 2024 by The American Society of Hematology.
Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
URI: http://hdl.handle.net/2433/286818
DOI(出版社版): 10.1182/bloodadvances.2023010598
PubMed ID: 38100431
関連リンク: https://www.kyoto-u.ac.jp/ja/research-news/2023-12-19-0
出現コレクション:学術雑誌掲載論文等

アイテムの詳細レコードを表示する

Export to RefWorks


出力フォーマット 


このアイテムは次のライセンスが設定されています: クリエイティブ・コモンズ・ライセンス Creative Commons